eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2024
vol. 28
 
Share:
Send email
Share:
abstract:
Original paper

Treatment outcomes of patients with BRAFV600E-mutated metastatic colorectal cancer: a Polish retrospective cohort study

Jolanta Żok
1
,
Michał Bieńkowski
2
,
Barbara Radecka
3
,
Agata Kuchar
1
,
Szymon Borowiec
1
,
Joanna Streb
4, 5
,
Michał Jurczyk
5, 6
,
Anna Jakieła-Drąg
7
,
Marek Gełej
3
,
Patryk Zając
3
,
Małgorzata Ploch-Glapińska
7
,
Renata Duchnowska
1

  1. Department of Oncology, Military Institute of Medicine, National Research Institute, Warsaw, Poland
  2. Department of Pathomorphology, Medical University of Gdańsk, Gdańsk, Poland
  3. Department of Oncology, Institute of Medical Science, University of Opole, Opole, Poland
  4. Department of Oncology, Jagiellonian University Medical College, University Hospital, Kraków, Poland
  5. Department of Oncology, Jagiellonian University Medical College, Kraków, Poland
  6. Department of Pathophysiology, Jagiellonian University Medical College, Kraków, Poland
  7. Department of Oncology, 4th Military Clinical Hospital with Polyclinic, Wrocław, Poland
Contemp Oncol (Pozn) 2024; 28 (4): 297–303
DOI: https://doi.org/10.5114/wo.2024.146953
Online publish date: 2025/01/15
View full text Get citation
 
PlumX metrics:
Introduction:
The BRAFV600E mutation is found in 6–11% of metastatic colo­rectal cancer (mCRC) patients. According to international guidelines for BRAFV600E-mutated mCRC, the triplet chemotherapy FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, irinotecan) or double chemotherapy with or without bevacizumab, and encorafenib plus cetuximab should be considered in the first- and second-line settings. We aimed to evaluate clinical practices in BRAFV600E-mutated mCRC patients treated at five Polish oncology centers.

Material and methods:
We retrospectively analyzed the data of BRAFV600E- mutated mCRC patients treated between 2011 and 2023. Before starting the first-line treatment, all patients were tested for BRAF and RAS mutations.

Results:
One hundred twenty-six patients (median age: 68 years; 55% female, 45% male) from five oncology centers were included. The majority of patients (69, 55%) had a right-sided primary tumor. The first line of chemotherapy was received by 100 patients (79.4%). The majority received doublet chemotherapy: FOLFOX (folinic acid, 5-fluorouracil, oxaliplatin), FOLFIRI (folinic acid, 5-fluorouracil, irinotecan), XELOX (capecitabine, oxaliplatin), and FOLFIRI with bevacizumab: 30 (30%), 47 (47%), 5 (5%), and 3 (3%). Only three patients received FOLFOXIRI; one patient received bevacizumab. The median duration of first-line treatment was 5.26 months (95% CI: 0.03–18.9). Subsequently, 40%, 16%, 5%, and 1% of patients received second, third, fourth, and fifth-line therapy, retrospectively. During the median follow-up of 38.5 months, 96 (79.3%) patients died. The median overall survival from the time of mCRC diagnosis was 13.7 months (95% CI: 11.3–17.6).

Conclusions:
This study highlights the unmet need for effective treatment strategies for patients with BRAFV600E-mutated mCRC in Poland.

keywords:

clinical practice, targeted therapy, BRAFV600E mutation, chemotherapy, metastatic colorectal cancer
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.